Hemagglutinin (HA) is a glycoprotein found on the surface of the influenza viruses. It plays a crucial role in the virus’s ability to infect host cells. The HA protein is responsible for binding the virus to the cell that is being infected. Influenza A virus H3N2 is one of the subtypes of the influenza virus that has been a significant cause of seasonal flu outbreaks in humans.
The HA protein is composed of two subunits, HA1 and HA2, which are derived from a single polypeptide precursor, HA0. The HA1 subunit contains the receptor-binding site, while the HA2 subunit is involved in the fusion of the viral and cellular membranes. The HA protein undergoes antigenic drift, which is the gradual accumulation of mutations in the HA gene, leading to changes in the antigenic properties of the virus. This antigenic drift is a major reason why influenza vaccines need to be updated regularly.
The H3N2 subtype of the influenza A virus first emerged in humans in 1968, causing a pandemic known as the “Hong Kong flu.” This subtype has continued to circulate in the human population, causing seasonal flu outbreaks. The H3N2 virus is known for its rapid antigenic drift, which makes it challenging to develop effective vaccines.
The Perth 16/09 strain of the H3N2 virus was identified in 2009. This strain has been included in seasonal influenza vaccines due to its prevalence and antigenic properties. The recombinant form of the HA protein from this strain is used in research and vaccine development to study immune responses and to develop more effective vaccines.
Recombinant HA proteins are produced using genetic engineering techniques. These proteins are used in various applications, including vaccine development and serological assays. The recombinant HA from the Perth 16/09 strain is particularly valuable for studying the immune response to the H3N2 virus and for developing vaccines that can provide broader protection against different strains of the virus.